Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study

ConditionProstate CA
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-100
SponsorQueen Mary University of London

About this trial

The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer.

The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people.

Anyone with a prostate can get prostate cancer. The prostate remains after genital (lower) surgery. The hormones and surgeries that trans women and non-binary people might have can lower the PSA. We do not have good data on the normal PSA levels are for this group

TransPRIDE is a research study that will help us find the normal levels of PSA in trans women and non-binary people with prostates.

Researchers will ask 500 trans women and non-binary people with prostates to take part. They will need to be aged 40 or over. They will need to be on hormones or have had lower surgery. They will be called after 6 months to recheck their health. If a person has a high PSA, they may be sent for more tests.

Knowing the normal PSA level for trans women and non-binary people will help doctors to find and treat their prostate cancer more quickly.

Eligibility criteria

Qualifiers

• Aged >40

Transgender or non-binary (identify with a gender other than the one assigned at birth)

With a prostate

Taking oestradiol for at least the last 3 months

Disqualifiers

• History of prostate cancer (Prostate cancer) at any time

History of prostate surgery at any time

History of prostate radiotherapy at any time

History of benign prostatic hypertrophy (enlarged prostate) at any time

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

500 Participants
are grouped into 4 trial groups